OTCMKTS:RSLSReshape Lifesciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Reshape Lifesciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.00 -1.50 (-33.33 %) (As of 04/9/2020 01:29 AM ET) Add Compare Share Today's Range$3.00Now: $3.00▼$3.0050-Day Range$3.00MA: $5.59▼$7.8552-Week Range$2.91Now: $3.00▼$23.40Volume16 shsAverage Volume1,594 shsMarket Capitalization$1.06 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media ReShape Lifesciences Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Its product portfolio also comprises ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Reshape Lifesciences. Previous Next 2.5 Community Rank Outperform VotesReshape Lifesciences has received 390 “outperform” votes. (Add your “outperform” vote.)Underperform VotesReshape Lifesciences has received 400 “underperform” votes. (Add your “underperform” vote.)Community SentimentReshape Lifesciences has received 50.63% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote “Outperform” if you believe RSLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldReshape Lifesciences does not currently pay a dividend.Dividend GrowthReshape Lifesciences does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Reshape Lifesciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsOnly 0.02% of the stock of Reshape Lifesciences is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioReshape Lifesciences has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.23 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolOTCMKTS:RSLS Previous Symbol CUSIP29365M20 CIK1371217 Webhttp://www.reshapelifesciences.com/ Phone949-429-6680Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio1.07Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$610,000.00 Price / Sales1.74 Cash Flow$42.86 per share Price / Cash Flow0.07 Book Value$341.84 per share Price / Book0.01Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-81,150,000.00 Net Margins-668.58% Return on Equity-163.22% Return on Assets-52.10%Miscellaneous EmployeesN/A Outstanding Shares354,000Market Cap$1.06 million Next Earnings Date5/18/2020 (Estimated) OptionableNot Optionable Receive RSLS News and Ratings via Email Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter. OTC:RSLS Rates by TradingView Reshape Lifesciences (OTCMKTS:RSLS) Frequently Asked Questions How has Reshape Lifesciences' stock been impacted by COVID-19 (Coronavirus)? Reshape Lifesciences' stock was trading at $5.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RSLS shares have decreased by 45.9% and is now trading at $3.00. View which stocks have been most impacted by Coronavirus. When is Reshape Lifesciences' next earnings date? Reshape Lifesciences is scheduled to release its next quarterly earnings announcement on Monday, May 18th 2020. View our earnings forecast for Reshape Lifesciences. How were Reshape Lifesciences' earnings last quarter? Reshape Lifesciences Inc (OTCMKTS:RSLS) issued its earnings results on Tuesday, August, 14th. The medical device company reported ($672.00) earnings per share for the quarter, missing analysts' consensus estimates of ($250.60) by $421.40. The medical device company earned $0.65 million during the quarter. Reshape Lifesciences had a negative net margin of 668.58% and a negative return on equity of 163.22%. View Reshape Lifesciences' earnings history. When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work? Shares of Reshape Lifesciences reverse split on the morning of Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 7th 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 1 shares after the split. Has Reshape Lifesciences been receiving favorable news coverage? News headlines about RSLS stock have been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Reshape Lifesciences earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave media coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutReshape Lifesciences. Who are some of Reshape Lifesciences' key competitors? Some companies that are related to Reshape Lifesciences include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Insulet (PODD) and Masimo (MASI). What other stocks do shareholders of Reshape Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Reshape Lifesciences investors own include XOMA (XOMA), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC), DryShips (DRYS), La Jolla Pharmaceutical (LJPC), Neovasc (NVCN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), Clovis Oncology (CLVS) and Inovio Pharmaceuticals (INO). Who are Reshape Lifesciences' key executives? Reshape Lifesciences' management team includes the following people: Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57) What is Reshape Lifesciences' stock symbol? Reshape Lifesciences trades on the OTCMKTS under the ticker symbol "RSLS." How do I buy shares of Reshape Lifesciences? Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Reshape Lifesciences' stock price today? One share of RSLS stock can currently be purchased for approximately $3.00. How big of a company is Reshape Lifesciences? Reshape Lifesciences has a market capitalization of $1.06 million and generates $610,000.00 in revenue each year. View additional information about Reshape Lifesciences. What is Reshape Lifesciences' official website? The official website for Reshape Lifesciences is http://www.reshapelifesciences.com/. How can I contact Reshape Lifesciences? Reshape Lifesciences' mailing address is 1001 Calle Amanecer, Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: How to Calculate Compound Annual Growth Rate (CAGR)
